CXCR4-tropic, but not CCR5-tropic, human immunodeficiency virus infection is inhibited by the lipid raft-associated factors, acyclic retinoid analogs, and cholera toxin B subunit

AIDS Research and Human Retroviruses

Volumn 29, Issue 2, 2013, Pages 279-288

  Kamiyama, Haruka ^a,b   Kakoki, Katsura ^a   Shigematsu, Sayuri ^a   Izumida, Mai ^a   Yashima, Yuka ^a   Tanaka, Yuetsu ^c   Hayashi, Hideki ^a   Matsuyama, Toshifumi ^a   Sato, Hironori ^a,d   Yamamoto, Naoki ^a,e   Sano, Tetsuro ^f   Shidoji, Yoshihiro ^b   Kubo, Yoshinao ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF NAGASAKI   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f KOWA COMPANY LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHOLERA TOXIN B SUBUNIT; GERANYLGERANOIC ACID; PERETINOIN; RETINOID DERIVATIVE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANTIVIRAL THERAPY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIPID RAFT; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; TARGET CELL; VIRAL TROPISM; VIRUS PARTICLE; VIRUS STRAIN;

ANTI-HIV AGENTS; CHOLERA TOXIN; DITERPENES; HIV-1; HUMANS; RECEPTORS, CXCR4; RECEPTORS, HIV; RETINOIDS; TRETINOIN; VIRAL TROPISM; VIRUS INTERNALIZATION;

EID: 84872968392     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0174     Document Type: Article

References (57)

1. Kolber MA: Development of drug resistance mutations in patients on highly active antiretroviral therapy: Does competitive advantage drive evolution. AIDS Rev 2007;9: 68-74. (Pubitemid 47162246)
2. Carter GC, Bernstone L, Sangani D, Bee JW, Harder T, and James W: HIV entry in macrophages is dependent on intact lipid rafts. Virology 2009;386:192-202.
3. Del Real G, Jimenez-Baranda S, Lacalle RA, et al.: Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. J Exp Med 2002;196:293-301. (Pubitemid 34875659)
4. Kamiyama H, Yoshii H, Tanaka Y, Sato H, Yamamoto N, and Kubo Y: Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection. Virology 2009;386:23-31.
5. Manes S, del Real G, Lacalle RA, et al.: Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep 2000;1:190-196.
6. Popik W, Alce TM, and Au WC: Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4 (+) T cells. J Virol 2002;76:4709-4722. (Pubitemid 34441677)
7. Michel V and Bakovic M: Lipid rafts in health and disease. Biol Cell 2007;99:129-140. (Pubitemid 46380925)
8. Waheed AA, Ablan SD, Mankowski MK, et al.: Inhibition of HIV-1 replication by amphotericin B methyl ester: Selection for resistant variants. J Biol Chem 2006;281:28699-28711. (Pubitemid 44507012)
9. Giguere JF and Tremblay MJ: Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004;78:12062-12065. (Pubitemid 39390792)
10. del Real G, Jimenez-Baranda S, Mira E, et al.: Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004;200:541-547. (Pubitemid 39121911)
11. Puri A, Rawat SS, Lin HM, et al.: An inhibitor of glycosphingolipid metabolism blocks HIV-1 infection of primary T-cells. AIDS 2004;18:849-858. (Pubitemid 38553705)
12. Mizrachi Y, Lev M, Harish Z, Sundaram SK, and Rubinstein A: L-Cycloserine, an inhibitor of sphingolipid biosynthesis, inhibits HIV-1 cytopathic effects, replication, and infectivity. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11: 137-141.
13. Hug P, Lin HM, Korte T, et al.: Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J Virol 2000;74:6377-6385. (Pubitemid 30429803)
14. Erdreich-Epstein A, Tran LB, Bowman NN, et al.: Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem 2002;277:49531- 49537. (Pubitemid 36014391)
15. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, and Reynolds CP: Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999;91: 1138-1146. (Pubitemid 29330552)
16. O'Donnell PH, Guo WX, Reynolds CP, and Maurer BJ: N-(4-Hydroxyphenyl) retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002;16:902-910. (Pubitemid 34537564)
17. Wang H, Maurer BJ, Reynolds CP, and Cabot MC: N-(4-Hydroxyphenyl) retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 2001;61: 5102-5105. (Pubitemid 32681541)
18. Wiegandt H, Helland R, and Radsak K: Retinoic acid alters the metabolic 3H-labelling of glycosphingolipids. Biochem Biophys Res Commun 1987;143:525-531. (Pubitemid 17045779)
19. Finnegan CM, Rawat SS, Puri A, Wang JM, Ruscetti FW, and Blumenthal R: Ceramide, a target for antiretroviral therapy. Proc Natl Acad Sci USA 2004;101:15452-15457. (Pubitemid 39441562)
20. Clarke CJ, Mediwala K, Jenkins RW, Sutton CA, Tholanikunnel BG, and Hannun YA: Neutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase. J Biol Chem 2011;286:21565-21576.
21. Nakashima H, Harada S, and Yamamoto N: Effect of retinoic acid on the replication of human immunodeficiency virus in HTLV-I-positive MT-4 cells. Med Microbiol Immunol 1987;176:189-198. (Pubitemid 17084742)
22. Anding AL, Chapman JS, Barnett DW, Curley RW Jr, and Clagett-Dame M: The unhydrolyzable fenretinide analogue 4-hydroxybenzylretinone induces the proapoptotic genes GADD153 (CHOP) and Bcl-2-binding component 3 (PUMA) and apoptosis that is caspase- dependent and independent of the retinoic acid receptor. Cancer Res 2007;67:6270-6277. (Pubitemid 47037509)
23. Finnegan CM and Blumenthal R: Fenretinide inhibits HIV infection by promoting viral endocytosis. Antiviral Res 2006; 69:116-123. (Pubitemid 43152046)
24. Sani BP and Meeks RG: Subacute toxicity of all-trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide. Toxicol Appl Pharmacol 1983;70:228-235. (Pubitemid 13003564)
25. Shidoji Y and Ogawa H: Natural occurrence of cancerpreventive geranylgeranoic acid in medicinal herbs. J Lipid Res 2004;45:1092-1103. (Pubitemid 38679505)
26. Araki H, Shidoji Y, Yamada Y, Moriwaki H, and Muto Y: Retinoid agonist activities of synthetic geranyl geranoic acid derivatives. Biochem Biophys Res Commun 1995;209:66-72.
27. Okamoto K, Sakimoto Y, Imai K, Senoo H, and Shidoji Y: Induction of an incomplete autophagic response by cancerpreventive geranylgeranoic acid (GGA) in a human hepatoma-derived cell line. Biochem J 2011;440:63-71.
28. Muto Y, Moriwaki H, Ninomiya M, et al.: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334:1561-1567. (Pubitemid 26177483)
29. Okusaka T, Ueno H, Ikeda M, and Morizane C: Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333. Hepatol Res 2011;41:542-552.
30. Baumgartner S, Mensink RP, and Plat J: Plant sterols and stanols in the treatment of dyslipidemia: New insights into targets and mechanisms related to cardiovascular risk. Curr Pharm Des 2011;17:922-932.
31. Gauthier S and Tremblay MJ: Cholera toxin inhibits HIV-1 replication in human colorectal epithelial HT-29 cells through adenylate cyclase activation. Antiviral Res 2011;88: 207-216.
32. Hammache D, Pieroni G, Yahi N, et al.: Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3. J Biol Chem 1998;273:7967-7971. (Pubitemid 28168845)
33. Soda Y, Shimizu N, Jinno A, et al.: Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun 1999;258:313-321. (Pubitemid 29287048)
34. Kubo Y, Yokoyama M, Yoshii H, et al.: Inhibitory role of CXCR4 glycan in CD4-independent X4-tropic human immunodeficiency virus type 1 infection and its abrogation in CD4-dependent infection. J Gen Virol 2007;88:3139-3144. (Pubitemid 350131256)
35. Kubo Y, Yoshii H, Kamiyama H, et al.: Ezrin, Radixin, and Moesin (ERM) proteins function as pleiotropic regulators of human immunodeficiency virus type 1 infection. Virology 2008;375:130-140.
36. Tobiume M, Takahoko M, Tatsumi M, and Matsuda M: Establishment of a MAGI-derived indicator cell line that detects the Nef enhancement of HIV-1 infectivity with high sensitivity. J Virol Methods 2001;97:151-158. (Pubitemid 32718749)
37. Tanaka R, Yoshida A, Murakami T, et al.: Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection. J Virol 2001;75:11534-11543. (Pubitemid 33063245)
38. Maciaszek JW, Coniglio SJ, Talmage DA, and Viglianti GA: Retinoid-induced repression of human immunodeficiency virus type 1 core promoter activity inhibits virus replication. J Virol 1998;72:5862-5869. (Pubitemid 28283373)
39. Hanley TM, Kiefer HL, Schnitzler AC, Marcello JE, and Viglianti GA: Retinoid-dependent restriction of human immunodeficiency virus type 1 replication in monocytes/macrophages. J Virol 2004;78:2819-2830. (Pubitemid 38314340)
40. Kiefer HL, Hanley TM, Marcello JE, Karthik AG, and Viglianti GA: Retinoic acid inhibition of chromatin remodeling at the human immunodeficiency virus type 1 promoter. Uncoupling of histone acetylation and chromatin remodeling. J Biol Chem 2004;279:43604-43613. (Pubitemid 39390663)
41. Chatterjee A, Bosch RJ, Hunter DJ, Manji K, Msamanga GI, and Fawzi WW: Vitamin A and vitamin B-12 concentrations in relation to mortality and morbidity among children born to HIV-infected women. J Trop Pediatr 2011;56:27-35.
42. Humphrey JH, Iliff PJ, Marinda ET, et al.: Effects of a single large dose of vitamin A, given during the postpartum period to HIV-positive women and their infants, on child HIV infection, HIV-free survival, and mortality. J Infect Dis 2006; 193:860-871.
43. Mehta S and Fawzi W: Effects of vitamins, including vitamin A, on HIV/AIDS patients. Vitam Horm 2007;75:355-383.
44. Semba RD, Ndugwa C, Perry RT, et al.: Effect of periodic vitamin A supplementation on mortality and morbidity of human immunodeficiency virus-infected children in Uganda: A controlled clinical trial. Nutrition 2005;21: 25-31. (Pubitemid 40127562)
45. Iordanskiy S, Iordanskaya T, Quivy V, Van Lint C, and Bukrinsky M: B-oligomer of pertussis toxin inhibits HIV-1 LTR-driven transcription through suppression of NFkappaB p65 subunit activity. Virology 2002;302:195-206. (Pubitemid 35356867)
46. Alfano M, Schmidtmayerova H, Amella CA, Pushkarsky T, and Bukrinsky M: The B-oligomer of pertussis toxin deacti-vates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. J Exp Med 1999;190:597-605. (Pubitemid 29428644)
47. Alfano M, Pushkarsky T, Poli G, and Bukrinsky M: The Boligomer of pertussis toxin inhibits human immunodeficiency virus type 1 replication at multiple stages. J Virol 2000;74:8767-8770. (Pubitemid 30666729)
48. Rogers TS, Corey SJ, and Rosoff PM: Identification of a 43-kilodalton human T lymphocyte membrane protein as a receptor for pertussis toxin. J Immunol 1990;145:678-683. (Pubitemid 20252379)
49. Wong WS, Simon DI, Rosoff PM, Rao NK, and Chapman HA: Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: Role of Mac-1(CD11b/CD18) and urokinase receptor (CD87). Immunology 1996;88:90-97. (Pubitemid 26167271)
50. Kang SM, Yao Q, Guo L, and Compans RW: Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J Virol 2003;77:9823-9830. (Pubitemid 37122063)
51. Sun JB, Czerkinsky C, and Holmgren J: Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand J Immunol 2011; 71:1-11.
52. Villablanca EJ, Zhou D, Valentinis B, et al.: Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo. J Leukoc Biol 2008; 84:871-879.
53. Matsumoto T, Jimi S, Hara S, Takamatsu Y, Suzumiya J, and Tamura K: Am80 inhibits stromal cell-derived factor-1-induced chemotaxis in T-cell acute lymphoblastic leukemia cells. Leuk Lymphoma 2011;51:507-514.
54. Baker AM, Sauliere A, Gaibelet G, et al.: CD4 interacts constitutively with multiple CCR5 at the plasma membrane of living cells. A fluorescence recovery after photobleaching at variable radii approach. J Biol Chem 2007;282:35163-35168. (Pubitemid 350232458)
55. Gaibelet G, Planchenault T, Mazeres S, et al.: CD4 and CCR5 constitutively interact at the plasma membrane of living cells: A confocal fluorescence resonance energy transferbased approach. J Biol Chem 2006;281:37921-37929. (Pubitemid 46042096)
56. Percherancier Y, Lagane B, Planchenault T, et al.: HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains. J Biol Chem 2003;278:3153-3161. (Pubitemid 36805610)
57. Lefebvre B, Furt F, Hartmann MA, et al.: Characterization of lipid rafts from Medicago truncatula root plasma membranes: a proteomic study reveals the presence of a raftassociated redox system. Plant Physiol 2007;144:402-418. (Pubitemid 46941606)